Now Playing
|Videos|December 13, 2022
Case Presentation: A 72-Year-Old Male with Advanced Renal Cell Carcinoma (RCC)
Author(s)Eric Jonasch, MD
Eric Jonasch, MD, presents the case of a 72-year-old man with advanced renal cell carcinoma, shares his initial impression.
Advertisement
Episodes in this series
Advertisement
Related to this article
LITESPARK-012 data at ESMO 2026 show that adding belzutifan or quavonlimab to pembrolizumab/lenvatinib did not improve survival for advanced kidney cancer.
Updated ARC-20 data show casdatifan delivers durable responses and strong survival in clear cell renal cell carcinoma, alone and in key first-line combinations.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5